GlaxoSmithKline Pharma's recent downturn has led MarketsMojo to downgrade the stock to 'Sell', reflecting a negative shift in technical indicators and raising performance concerns.

GlaxoSmithKline Pharma has been hit with a tax demand of INR 2 crores for the fiscal year 2020-21, consisting primarily of INR 1.11 crores in TDS and INR 0.90 crores in interest. The company plans to appeal this decision.